ARGENICA THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.765 AUD | +6.25% |
|
+15.04% | +50.00% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 0.26 0.39 | Sales 2023 | 1.75 2.62 | Capitalization | 36.88M 55.27M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -5.99M | Net income 2023 | -4M -5.99M | EV / Sales 2022 | 109,850,751 x |
| Net cash position 2022 | 8.91M 13.36M | Net cash position 2023 | 9.34M 13.99M | EV / Sales 2023 | 15,739,424 x |
| P/E ratio 2022 |
-7.77
x | P/E ratio 2023 |
-6.82
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.43% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.25% | ||
| 1 week | +15.04% | ||
| Current month | +30.77% | ||
| 1 month | +34.21% | ||
| 3 months | +37.84% | ||
| 6 months | +91.25% | ||
| Current year | +50.00% |
1 week
0.63
0.77
1 month
0.540.77
Current year
0.470.77
1 year
0.300.77
3 years
0.181.02
5 years
0.181.02
10 years
0.181.02
| Managers | Title | Age | Since |
|---|---|---|---|
Liz Dallimore
CEO | Chief Executive Officer | - | - |
Emma Waldon
DFI | Director of Finance/CFO | - | - |
Meghan Thomas
CTO | Chief Tech/Sci/R&D Officer | - | 22-04-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Terry C. Budge
BRD | Director/Board Member | 72 | - |
Geoff Pocock
BRD | Director/Board Member | - | - |
Dianne Angus
BRD | Director/Board Member | 63 | Nov. 30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.765 | +6.25% | 711 082 |
| 24-05-20 | 0.72 | +7.46% | 565,610 |
| 24-05-17 | 0.67 | -0.74% | 58,087 |
| 24-05-16 | 0.675 | -4.93% | 200,687 |
| 24-05-15 | 0.71 | +9.23% | 536,137 |
Delayed Quote Australian S.E., May 21, 2024 at 02:10 am EDT
More quotes
Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
Calendar
2024-08-20
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +50.00% | 59.05M | |
| +39.37% | 54.04B | |
| +44.87% | 41.96B | |
| -1.40% | 41.92B | |
| -7.20% | 28.35B | |
| +12.47% | 26.35B | |
| -21.76% | 19B | |
| +6.98% | 13B | |
| +29.20% | 12.28B | |
| +26.32% | 12.19B |
- Stock Market
- Equities
- AGN Stock
